Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (1475 total)
-
Creator: The REMAP-CAP Investigators
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-25
Description: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. -
Creator: The RECOVERY Collaborative Group.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-25
Description: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. -
Creator: The RECOVERY Collaborative Group.
Subject: Research
Item Type: Publication
Date Last Updated: 2020-07-17
Description: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-02
Description: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.A response to this article was… -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-19
Description: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials. -
Creator: the PlasmAr Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled… -
Creator: the Pipeline and Hazardous Materials Safety Administration
Subject: Waste Management
Item Type: Guide
Date Last Updated: 2005-05-19
Description: The requirements adopted for the UN Recommendations establish a two-tiered classification system for Division 6.2 materials—Category A and Category B. A Category A infectious substance poses a higher degree of risk than a Category B infectious… -
Creator: the Oxford University Hospitals Staff Testing Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-11
Description: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: the Oxford COVID-19 Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-30
Description: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Creator: the Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-19
Description: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks.